XTL Biopharmaceuticals Ltd. (XTLB) |
| 2.445 0.05 (2.09%) 04-14 16:00 |
| Open: | 2.4 |
| High: | 2.52 |
| Low: | 2.365 |
| Volume: | 8,063 |
| Market Cap: | 1(M) |
| PE Ratio: | -0.68 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.96 |
| Resistance 1: | 2.67 |
| Pivot price: | 2.48 |
| Support 1: | 2.20 |
| Support 2: | 1.83 |
| 52w High: | 10.28 |
| 52w Low: | 2.12 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Financials
| EPS | -3.600 |
| Book Value | -0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.949 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -853.58 |
| Return on Assets (ttm) | -240.6 |
| Return on Equity (ttm) | -577.1 |
Company news
Sun, 29 Mar 2026
XTLB PE Ratio & Valuation, Is XTLB Overvalued - Intellectia AI
Mon, 23 Mar 2026
XTL Biopharmaceuticals (XTLB) CFO Niv Segal files initial Form 3 - Stock Titan
Mon, 23 Mar 2026
XTL Biopharmaceuticals (XTLB) director discloses options on 1,000,000 shares - Stock Titan
Sat, 21 Mar 2026
XTL Biopharmaceuticals Announces ADS Ratio Change - The Manila Times
Tue, 10 Mar 2026
XTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI Expires - TipRanks
Fri, 27 Feb 2026
XTL Biopharmaceuticals faces Nasdaq delisting notice - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
